Table 1.
Demographic and clinical data of the study population.
| Variable | Preterm BPD (n = 57) | Preterm no BPD (n = 114) | P |
|---|---|---|---|
| Gestational age (weeks)* | 27 (25, 28) | 26.5 (25, 28) | 0.7 |
| Birthweight (g)* | 706 (611, 884) | 730 (630, 895) | 0.1 |
| Antenatal steroids | 55 (96.5) | 106 (93) | 0.5 |
| Fetal growth restriction | 21 (37) | 5 (4.4) | <0.001 |
| Male sex | 32 (56) | 69 (60.5) | 0.6 |
| 5 min Apgar score^ | 7 (0–10) | 7 (1–9) | 0.6 |
| Umbilical artery catheter | 35 (56) | 52 (45.6) | 0.07 |
| Surfactant | 51 (89.5) | 100 (87.7) | 0.8 |
| PDA | 46 (81) | 28 (24.5) | <0.001 |
| PDA therapy amongst those diagnosed with PDA | 42 (91.3) | 20 (71.4) | 0.047 |
| Postnatal steroids | 32 (56%) | 17 (15%) | <0.001 |
| Maternal diabetes | 10 (8.7%) | 4 (7%) | 0.7 |
| Pre-eclampsia | 18 (16%) | 6 (10.5%) | 0.5 |
| Chorioamnionitis | 12 (10.5%) | 7 (12%) | 0.8 |
| Duration of any respiratory support, days, median (range) | 96 (58–138) | 44 (10–89) | <0.001 |
Data presented as *median (interquartile range), ^median (range). Rest all data in n (%),
PDA Patent ductus arteriosus, BPD Bronchopulmonary dysplasia.